# Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines

> **NCT00370318** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 400 (—)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** 10 valent pneumococcal conjugate vaccine
- **BIOLOGICAL:** Infanrix Hexa
- **BIOLOGICAL:** Rotarix
- **DRUG:** Paracetamol

## Key facts

- **NCT ID:** NCT00370318
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 400 (—)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00370318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00370318, "Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00370318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*